Your browser doesn't support javascript.
loading
Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 573-576, 2020.
Artículo en Chino | WPRIM | ID: wpr-862880
ABSTRACT
At present, there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma (NHL). Histone deacetylase inhibitors (HDACi) exert anti-tumor effects by inhibiting the activation of histone deacetylase (HDAC) and regulating gene expression. HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL. This article reviews the progress of HDACi in the treatment of NHL.
Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Guía de Práctica Clínica Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Guía de Práctica Clínica Idioma: Chino Revista: Journal of Leukemia & Lymphoma Año: 2020 Tipo del documento: Artículo